Sarvottam Finvest Limited disclosed its unaudited financial results for the quarter ended June 30, 2026, through a regulatory filing under SEBI Listing Regulations.

Board Meeting Details

The Board of Directors meeting was held on August 8, 2026, based on the recommendation of the Audit Committee. The meeting commenced at 16:00 and concluded at 17:30.

Financial Results (All figures in ₹ lakhs)

Income Statement for Quarter Ended June 30, 2026:

  • Interest Income: 38.41
  • Dividend Income: 0.02
  • Sale of investments (held for trading): 9.10
  • Net gain on fair value changes: 16.20
  • Gain/(Loss) on sale of Investments: 0.03
  • Gain/(Loss) on Equity Derivatives: 0.82
  • Others: 1.97
  • Total Income: 66.55

Expenses:

  • Finance Cost: -
  • Net loss on fair value changes: -
  • Impairment on Financial instruments: 25.00
  • Purchase of investments (held for trading): -
  • Changes in inventories of investments (held for trading): 3.18
  • Employee Benefits Expense: 9.22
  • Depreciation and Amortisation Expenses: 0.11
  • Contingent Provisions for standard assets: -
  • Other Expenditure: 17.15
  • Total Expenses: 54.66

Profit/(Loss) before Tax: 11.89

Tax Expenses:

  • Current Tax: 4.14
  • Deferred Tax: 2.69
  • Earlier year Tax: -

Net Profit/(Loss) for the period: 5.06

Earnings per Share (Basic & Diluted): ₹0.07 (Not Annualized)

Comparative Figures

Quarter Ended June 30, 2026 vs. Previous Periods:

  • March 31, 2026 (Audited): Net Loss of ₹24.30 lakh
  • June 30, 2025 (Reviewed): Net Profit of ₹15.52 lakh
  • March 31, 2026 (Audited): EPS of (₹0.32)

Capital Structure

  • Paid up Equity Share Capital: ₹750.00 lakh (Face Value ₹10 per Share) - unchanged from previous periods
  • Other Equity: Not specified for current quarter

Segment Information

The company operates in a single primary segment of 'Financing', making segment disclosure under Ind AS 108 not applicable.

Accounting Framework

The financial statement was prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013.